Analyst consensus rating
ORIC Pharmaceuticals Analyst Rating: Strong Buy
Direct answer
ORIC Pharmaceuticals's consensus rating is Strong Buy.
14 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $21.64.
Forecast evidence checked October 18, 2026.
Get free ORIC Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $12.35
- Average price target
- $21.64
- High price target
- $27.00
- Low price target
- $14.00
- Low target gap
- +13.4%
- Target upside
- +75.2%
- High target gap
- +118.6%
- Target range width
- 105.3%
- Consensus rating
- Strong Buy
- Analysts
- 14
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ORIC Pharmaceuticals?
ORIC Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $21.64.
How far are ORIC Pharmaceuticals's low and high targets from the recorded price?
The low target implies +13.4%, while the high target implies +118.6%.
How many analysts are included in ORIC Pharmaceuticals's consensus?
The verified consensus includes 14 analysts.
How is ORIC Pharmaceuticals's target upside or downside calculated?
The average target of $21.64 is divided by the recorded price of $12.35, then one is subtracted to produce +75.2%. This does not guarantee a future return.
When was ORIC Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.